WO2024254448A3 - Nanoformulations de promédicament de boronate dans des traitements de maladies - Google Patents

Nanoformulations de promédicament de boronate dans des traitements de maladies Download PDF

Info

Publication number
WO2024254448A3
WO2024254448A3 PCT/US2024/033004 US2024033004W WO2024254448A3 WO 2024254448 A3 WO2024254448 A3 WO 2024254448A3 US 2024033004 W US2024033004 W US 2024033004W WO 2024254448 A3 WO2024254448 A3 WO 2024254448A3
Authority
WO
WIPO (PCT)
Prior art keywords
boronate
amb
nanoplatform
nanoformulations
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033004
Other languages
English (en)
Other versions
WO2024254448A2 (fr
Inventor
Dandan Guo
Juntao Luo
Changying SHI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of WO2024254448A2 publication Critical patent/WO2024254448A2/fr
Publication of WO2024254448A3 publication Critical patent/WO2024254448A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'amphotéricine B (AmB) est la référence standard pour le traitement d'infections fongiques systémiques potentiellement mortelles. Pour développer des formulations d'AmB économiques à toxicité réduite, des modes de réalisation divulgués introduisent un nombre contrôlé de fractions d'acide phénylboronique (PBA) dans une nanoplateforme de télodendrimère (TD) pour optimiser la conjugaison AmB via une stratégie d'ester de boronate réversible. Cette nanoplateforme de TD de boronate flexible multivalent peut également être appliquée dans le développement de promédicaments pour différentes molécules de médicament contenant du cis-diol ou molécules de médicament contenant de l'hydroxyle cétone α- ou β-.
PCT/US2024/033004 2023-06-07 2024-06-07 Nanoformulations de promédicament de boronate dans des traitements de maladies Ceased WO2024254448A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363471669P 2023-06-07 2023-06-07
US63/471,669 2023-06-07

Publications (2)

Publication Number Publication Date
WO2024254448A2 WO2024254448A2 (fr) 2024-12-12
WO2024254448A3 true WO2024254448A3 (fr) 2025-01-30

Family

ID=93794615

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033004 Ceased WO2024254448A2 (fr) 2023-06-07 2024-06-07 Nanoformulations de promédicament de boronate dans des traitements de maladies

Country Status (1)

Country Link
WO (1) WO2024254448A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5098417A (en) * 1990-04-12 1992-03-24 Ricoh Kyosan, Inc. Cellulosic wound dressing with an active agent ionically absorbed thereon
US20150045419A1 (en) * 2011-05-13 2015-02-12 The Regents Of The University Of California Reversibly crosslinked micelle systems
WO2021126970A1 (fr) * 2019-12-17 2021-06-24 The Regents Of The University Of California Ciblage séquentiel dans la réticulation de nanothéranostiques pour le traitement de tumeurs cérébrales
US20210346518A1 (en) * 2018-08-31 2021-11-11 The Regents Of The University Of California Cyanine-based telodendrimers and uses for treating cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5098417A (en) * 1990-04-12 1992-03-24 Ricoh Kyosan, Inc. Cellulosic wound dressing with an active agent ionically absorbed thereon
US20150045419A1 (en) * 2011-05-13 2015-02-12 The Regents Of The University Of California Reversibly crosslinked micelle systems
US20210346518A1 (en) * 2018-08-31 2021-11-11 The Regents Of The University Of California Cyanine-based telodendrimers and uses for treating cancer
WO2021126970A1 (fr) * 2019-12-17 2021-06-24 The Regents Of The University Of California Ciblage séquentiel dans la réticulation de nanothéranostiques pour le traitement de tumeurs cérébrales

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHENG GUODONG, ZHENG JIAHUI, XIAO LE, SHANG TONGYI, CAI YANJUN, LI YUWEI, XU YIMING, CHEN XIAOMING, LIU YUN, YANG BIN: "Construction of a Phenylboronic Acid-Functionalized Nano-Prodrug for pH-Responsive Emodin Delivery and Antibacterial Activity", ACS OMEGA, ACS PUBLICATIONS, US, vol. 6, no. 12, 30 March 2021 (2021-03-30), US , pages 8672 - 8679, XP093271154, ISSN: 2470-1343, DOI: 10.1021/acsomega.1c00606 *

Also Published As

Publication number Publication date
WO2024254448A2 (fr) 2024-12-12

Similar Documents

Publication Publication Date Title
Hammond 3 biological activity of polyene antibiotics
MX9304485A (es) Formulacion solida, oral, de liberacion controlada, que incluye complejos hidrofilicos aglomerados con caracteristicas de liberacion multifasicas.
WO2001062300A3 (fr) Therapie par promedicaments actives par une caspase
LV11430A (lv) 2-Piridilmetilenpoliazamakrociklofosfonskabes to kompleksi un atvasinajumi izmantosanai par kontrastvielam
DK1248613T3 (da) Clonidinpræparater
WO2006065392A3 (fr) Traitements anti-cancereux
WO1999002186A3 (fr) Systeme d'administration d'antigene comprenant des derives de monoglyceride ou de diglyceride en tant qu'adjuvants
HK26584A (en) Injection solutions containing micelle-forming agents
ES2144039T3 (es) Procedimiento y dispositivo para el abombado de hojas de vidrio.
ATE463261T1 (de) Meningokokken-konjugat-impfung
WO2004111199A3 (fr) Systemes et procedes de traitement de maladies inflammatoires et proliferatives humaines et de lesions au moyen d'inhibiteurs du metabolisme des acides gras et/ou d'inhibiteurs glycolytiques
IL198783A0 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
WO2002015938A8 (fr) Nouvelle formulation de testosterone decanoate pour le traitement de l'homme
ATE512670T1 (de) Meningokokken-konjugat-impfung
DE69726712T2 (de) Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthält
WO2024254448A3 (fr) Nanoformulations de promédicament de boronate dans des traitements de maladies
WO2004112717A3 (fr) Conjugue destine au ciblage specifique d'agents anticancereux sur des cellules cancereuses, et production du conjugue
WO2007064968A3 (fr) Compositions pharmaceutiques stables de 5,10 methylenetetrahydrofolate
WO2002043739A3 (fr) Formulations dermatologiques
WO2007044348A8 (fr) Produits hygieniques anti-infectieux a base de phtalate d'acetate de cellulose
AU5487101A (en) Cosmetic or dermatological product comprising a freeze-dried hydrocolloid composition
WO2001051021A3 (fr) Utilisation de la dhea ou certains de ses derives pour ameliorer l'aspect papyrace de la peau
AU7335300A (en) Treatment of fungal infections utilizing a fungal growth medium
WO2007092299A3 (fr) Conjugués ciblés et radiation
PT1878431E (pt) Agente medicinal para a prevenção da progressão de alterações apoptóticas e jugulares necróticas nos tecidos do organismo

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE